Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Combining glucagon-like peptide-1 receptor agonists (GLP-1RAs) and sodium-glucose cotransporter-2 inhibitors (SGLT2is) in patients with type 2 diabetes mellitus (T2DM)
Pierre Gourdy, Patrice Darmon, François Diévart, et al.
Cardiovascular Diabetology (2023) Vol. 22, Iss. 1
Open Access | Times Cited: 57

Showing 26-50 of 57 citing articles:

Improved glycemic and weight control with Dulaglutide addition in SGLT2 inhibitor treated obese type 2 diabetic patients at high cardiovascular risk in a real-world setting. The AWARE -2 study
Cesare Berra, Roberto Manfrini, Francesco Bifari, et al.
Pharmacological Research (2024) Vol. 210, pp. 107517-107517
Open Access | Times Cited: 3
Recent Advances and Future Challenges in the Immunology of Islet and Stem Cell-Derived Islet Transplantation
Adrian Kee Keong Teo, Kahbing Jasmine Tan, Ye Xin Koh, et al.
Elsevier eBooks (2025)
Closed Access
Diabetic Ketoacidosis and the Use of New Hypoglycemic Groups: Real-World Evidence Utilizing the Food and Drug Administration Adverse Event Reporting System
Hilal Thaibah, Otilia J.F. Banji, David Banji, et al.
Pharmaceuticals (2025) Vol. 18, Iss. 2, pp. 214-214
Open Access
Safety, efficacy, and cardiovascular benefits of combination therapy with SGLT-2 inhibitors and GLP-1 receptor agonists in patients with diabetes mellitus: a systematic review and meta-analysis of randomized controlled trials
Asma Mousavi, Shayan Shojaei, Hamidreza Soleimani, et al.
Diabetology & Metabolic Syndrome (2025) Vol. 17, Iss. 1
Open Access
Antidiabetic combination therapy and cardiovascular outcomes: An evidence-based approach
Vanishri Ganakumar, Cornelius James Fernandez, Joseph M Pappachan
World Journal of Diabetes (2025) Vol. 16, Iss. 4
Closed Access
Combining GLP-1 Receptor Agonists and SGLT2 Inhibitors in Type 2 Diabetes Mellitus: A Scoping Review and Expert Insights for Clinical Practice Utilizing the Nominal Group Technique
Carlos Augusto Yepes, Isabel C. Cardenas-Moreno, Rodrigo Daza-Arnedo, et al.
Diabetes Therapy (2025)
Open Access
Effects of SGLT2 inhibitors and GLP-1 receptor agonists on glycemic variability, islet cell function, and insulin resistance in patients with type 2 diabetes mellitus and renal cell carcinoma
Anqi Zhang, Xincheng Zhang, Aige Yang, et al.
American Journal of Cancer Research (2025) Vol. 15, Iss. 3, pp. 946-965
Closed Access
The Critical Role of GLP-1 Signaling Pathways in the Pathology of Parkinson's Disease and Diabetes
Jinhao Chen, Xiang Dong, Yi-Chen Lin, et al.
Pathology - Research and Practice (2025), pp. 155985-155985
Closed Access
Effect of beinaglutide, a thrice-daily GLP-1 receptor agonist, on body weight and metabolic parameters: A systematic review and meta-analysis
A. B. M. Kamrul‐Hasan, Vanishri Ganakumar, Lakshmi Nagendra, et al.
World Journal of Diabetes (2025) Vol. 16, Iss. 5
Closed Access
Conquering Insulin Network Dysfunctions in Alzheimer’s Disease: Where Are We Today?
Suzanne M. de la Monte
Journal of Alzheimer s Disease (2024) Vol. 101, Iss. s1, pp. S317-S343
Closed Access | Times Cited: 3
Influence of glucagon-like peptide-1 receptor agonists on fat accumulation in patients with diabetes mellitus and non-alcoholic fatty liver disease or obesity: A systematic review and meta-analysis of randomized control trials
Wanrun Xie, Zhenzhen Hong, Bo Li, et al.
Journal of Diabetes and its Complications (2024) Vol. 38, Iss. 6, pp. 108743-108743
Closed Access | Times Cited: 2
ARTERIAL HYPERTENSION AND DYSLIPIDEMIA IN PATIENTS WITH TYPE 2 DIABETES MELLITUS: RISK FACTORS, INTERVENTION STRATEGIES AND IMPACT ON CARDIOVASCULAR HEALTH.
Gabriel Rodrigues França, Vitor Silva Rosa, Eduardo Henrique Rezende, et al.
Brazilian Journal of Implantology and Health Sciences (2024) Vol. 6, Iss. 4, pp. 577-589
Open Access | Times Cited: 2
Hypoglycemic Drugs in Patients with Diabetes Mellitus and Heart Failure: A Narrative Review
Anastasia Nikolaidou, Ioannis Ventoulis, Georgios Karakoulidis, et al.
Medicina (2024) Vol. 60, Iss. 6, pp. 912-912
Open Access | Times Cited: 2
Cardiovascular and renal effects of the combination therapy of a GLP-1 receptor agonist and an SGLT2 inhibitor in observational real-life studies
André Scheen
Diabetes & Metabolism (2024), pp. 101594-101594
Closed Access | Times Cited: 2
The Effects of Sodium–Glucose Cotransporter 2 Inhibitors on Body Composition in Type 2 Diabetes Mellitus: A Narrative Review
Soodeh Jahangiri, Mojtaba Malek, Sanjay Kalra, et al.
Diabetes Therapy (2023) Vol. 14, Iss. 12, pp. 2015-2030
Open Access | Times Cited: 4
Adverse event reporting of combining SGLT2 inhibitor and GLP1 receptor agonist: a real-world study from FAERS
Chunyan Tian, Zheng Rong Yang, Subei Zhao, et al.
Nutrition Metabolism and Cardiovascular Diseases (2024) Vol. 35, Iss. 1, pp. 103758-103758
Closed Access | Times Cited: 1
Mechanism and Therapeutic Targets of Circulating Immune Cells in Diabetic Retinopathy
Bowen Zhao, Yin Zhao, Xufang Sun
Pharmacological Research (2024) Vol. 210, pp. 107505-107505
Open Access | Times Cited: 1
Comparative cardiovascular effectiveness of glucagon-like peptide-1 receptor agonists and sodium–glucose cotransporter-2 inhibitors in atherosclerotic cardiovascular disease phenotypes: a systematic review and meta-analysis
Yu‐Min Lin, Jheng-Yan Wu, Mei-Chuan Lee, et al.
European Heart Journal - Cardiovascular Pharmacotherapy (2024)
Closed Access | Times Cited: 1
Retrospective Longitudinal Observational Study on the Long-Term Effects of Sodium-Glucose Cotransporter-2 Inhibitors on the Development of Metabolic Dysfunction-Associated Steatotic Liver Disease in Type 2 Diabetic Japanese Patients
Hisayuki Katsuyama, Seiichi Horinaka, Mariko Hakoshima, et al.
Journal of Clinical Medicine (2024) Vol. 13, Iss. 16, pp. 4929-4929
Open Access | Times Cited: 1
GLP-1 receptor agonists and SGLT2 inhibitors: new anti-aging tools?
Gaetano Santulli, Pasquale Mone, Fahimeh Varzideh
Future Cardiology (2024), pp. 1-4
Open Access | Times Cited: 1
Thyroid hormone treatment counteracts cellular phenotypical remodeling in diabetic organs
Angelo Michele Lavecchia, Polyxeni Mantzouratou, Domenico Cerullo, et al.
iScience (2023) Vol. 26, Iss. 10, pp. 107826-107826
Open Access | Times Cited: 3
Ginsenoside Rb1 Promotes Hepatic Glycogen Synthesis to Ameliorate T2DM Through 15-PGDH/PGE2/EP4 Signaling Pathway
Mingjie Liang, Wenjing Zhan, Lexun Wang, et al.
Diabetes Metabolic Syndrome and Obesity (2023) Vol. Volume 16, pp. 3223-3234
Open Access | Times Cited: 3
Management of patients with hypertension and chronic kidney disease referred to Hypertension Excellence Centres among 27 countries. On behalf of the European Society of Hypertension Working Group on Hypertension and the Kidney
Jean‐Michel Halimi, Pantelis Sarafidis, Michel Azizi, et al.
Blood Pressure (2024) Vol. 33, Iss. 1
Open Access
Evaluating the effectiveness and safety of empagliflozin versus liraglutide in managing diabetic dyslipidemia: An observational study
Motakatla Usha Rani, Chitra Karuppiah, Penupothu Sree Nagamani
Asian Journal of Medical Sciences (2024) Vol. 15, Iss. 7, pp. 137-141
Open Access
Place des nouvelles classes thérapeutiques dans la stratégie de prise en charge du diabète de type 2
Pierre Gourdy
Pratiques en nutrition (2024)
Closed Access

Scroll to top